Back

NGFR as a biomarker and actionable target in cisplatin-based chemoradiotherapy-resistant HNSCC

2025-12-29 oncology Title + abstract only
View on medRxiv
Show abstract

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high mortality rates, often exhibiting resistance to conventional treatments such as radiotherapy (RT) or a combination of chemotherapy and radiotherapy (CRT). The nerve growth factor receptor (NGFR, also known as p75NTR or CD271) is a well-established cancer stem cell marker in melanoma, where it has been linked to resistance to multiple therapies. In HNSCC, NGFR has been reported as a poor prognostic marker, with it...

Predicted journal destinations